Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Also in attendance was Nikita Khrushchev of the Soviet Union. July 27: Austria becomes an independent country after the end of the Allied occupation. The last allied troops leave the country in October. August 15: The First Sudanese Civil War begins between the north and the south. November 1: MAAG Vietnam is organized, often regarded as the starting point of the Vietnam War.
=== By Dyson === Freeman Dyson at The New York Review of Books (content for subscribers only) "Heretical thoughts about science & society", essay by Freeman Dyson [8.7.2007] Templeton Prize acceptance lecture 2000, by Freeman Dyson Imagined Worlds by Freeman Dyson, 1996: Chapter 1 Video Interview of Freeman Dyson discussing Bogus Climate Models on YouTube A radio interview with Freeman Dyson Archived 7 August 2020 at the Wayback Machine Aired on the Lewis Burke Frumkes Radio Show in 2009. Suzan Mazur interviewing Dyson, 2012, CounterPunch "Pushing the Boundaries – A Conversation with Freeman Dyson" Archived 17 August 2016 at the Wayback Machine, Ideas Roadshow, 2014 Freeman Dyson and Gregory Benford: Forseeing the Next 35 Years – Where Will We Be in 2054? on YouTube, Arthur C. Clarke Center for Human Imagination, February 2019. A 'Rebel' Without a Ph.D.
Upon adding phenol to deuterated water (water containing D2O in addition to the usual H2O), a hydrogen-deuterium exchange is observed to affect phenol's hydroxyl group (resulting in C6H5OD), indicating that phenol readily undergoes hydrogen-exchange reactions with water. Mainly the hydroxyl group is affected—without a catalyst, the other five hydrogen atoms are much slower to undergo exchange—reflecting the difference in chemical environments between the hydroxyl hydrogen and the aryl hydrogens.
== Personal life == While he was in Uppsala Williams met Jelly Klara Büchli, a Dutch student from Groningen. They married in 1952 and then lived in Oxford. Jelly read English language and literature at St Hilda's College, Oxford between 1952 and 1955, but the birth of their first son, Timothy Ivor, interrupted her final exams. A second son, John M, was born in 1957. In 1981 Jelly published A Dutch Reader. Bob Williams died in the John Radcliffe Hospital on 21 March 2015.
Sources: en.wikipedia.org
Aarts, Mongolian fermented curd, eaten as a dried snack or reconstituted as a hot beverage Chongos zamoranos, a dessert prepared with milk curdled with sugar and cinnamon Cuajada (or Coalhada), usually sweetened and eaten for breakfast or dessert, popular in Spain and Central America Curd snack, a snack popular in the Baltic states Çökelek, a form of fermented buttermilk or yogurt curd from Turkey Farmer cheese Hoop cheese Key lime pie, prepared by curdling condensed milk Kesú Paraguay, a Paraguayan formed cottage cheese Kurt or Qurut, Central Asian cheese curd Leipäjuusto, Finnish cheese Ostkaka, Swedish style cheese cake, some call it a Swedish national dish Paskha, a Russian Easter dessert made of Tvorog Ricotta, an Italian whey cheese Skyr, Icelandic curd Tofu, the coagulated product from soy milk, from East and Southeast Asian countries. Túró Rudi, a Hungarian chocolate bar with curd Urdă, a Balkan fresh white cheese made from whey. List of dairy products
Native (i.e., elemental) selenium is a rare mineral, which does not usually form good crystals, but, when it does, they are steep rhombohedra or tiny acicular (hair-like) crystals. Isolation of selenium is often complicated by the presence of other compounds and elements. Selenium occurs naturally in several inorganic forms, including selenide, selenate, and selenite, but these minerals are rare. The common mineral selenite is not a selenium mineral, and contains no selenite ion, but is rather a type of gypsum (calcium sulfate dihydrate) named like selenium for the moon well before the discovery of selenium. Selenium is most commonly found as an impurity, replacing a small fraction of the sulfur in sulfide ores of many metals, particularly copper sulfide. In living systems, selenium is found in the amino acids selenomethionine, selenocysteine, and methylselenocysteine. In these compounds, selenium plays a role analogous to that of sulfur. Another naturally occurring organoselenium compound is dimethyl selenide. Certain soils are selenium-rich, and selenium can be bioconcentrated by some plants. In soils, selenium most often occurs in soluble forms such as selenate (analogous to sulfate), which are leached into rivers very easily by runoff. Ocean water contains significant amounts of selenium. Typical background concentrations of selenium do not exceed 1 ng/m3 in the atmosphere; 1 mg/kg in soil and vegetation and 0.5 μg/L in freshwater and seawater, 0.05 – 0.09 mg/kg average crustal abundance.
=== Protein assembly === After initiation, elongation, and termination, there is a fourth step of the disassembly of the post-termination complex of ribosome, mRNA, and tRNA, which is a prerequisite for the next round of protein synthesis. The large ribosomal subunit has a role in protein folding both in vitro and in vivo. The large ribosomal subunit provides a hydrophobic surface for the hydrophobic collapse step of protein folding. The newly synthesized protein needs full access to the large subunit to fold; this process may take a period of time (5 minutes for beta-galactosidase).
Despite being formally abolished in the 1960s, slavery in Yemen remains a significant issue exacerbated by ongoing conflict and socio-economic instability. An estimated 85,000 people remaining enslaved as of 2022. The Iran-backed Houthi militias have been accused of reinstating traditional slavery systems. Reports indicate that over 1,800 Yemenis have been forced into servitude by prominent Houthi leaders, with the Houthis dividing society into hierarchical classes of masters and slaves.
== References == Coe, Sophie D. (1994), America's First Cuisines, ISBN 0-292-71159-X Foster, Nelson. Chilies to Chocolate: Food the Americas Gave the World. The Univ. of Arizona Press. Jacobsen, Sven-Erik. "The Worldwide Potential for Quinoa (Chenopodium quinoa Willd.)." Food Reviews International 19.1-2 (2003): 167-177. Jennings, Justin & Guy Duke, ‘Making the typical exceptional: the elevation of Inca cuisine’, in The Oxford Handbook of the Incas. Eds. Sonia Alconini & R. Alan Covey. New York: Oxford University Press, 2018. Popenoe, Hugh, Steven R. King, Jorge Leon, Luis Sumar Kalinowski, and Noel D. Vietmeyer (1989), Lost Crops of the Incas, ISBN 0-309-04264-X
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.